Compare FGBI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | NSRX |
|---|---|---|
| Founded | 1934 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 63.4M |
| IPO Year | N/A | 2025 |
| Metric | FGBI | NSRX |
|---|---|---|
| Price | $8.09 | $7.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 26.7K | 9.4K |
| Earning Date | 01-30-2026 | 02-15-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,036,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.31 | $5.90 |
| 52 Week High | $10.85 | $9.99 |
| Indicator | FGBI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 83.87 | N/A |
| Support Level | $7.50 | N/A |
| Resistance Level | $7.75 | N/A |
| Average True Range (ATR) | 0.37 | 0.00 |
| MACD | 0.18 | 0.00 |
| Stochastic Oscillator | 99.67 | 0.00 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.